Abstract: The invention provides a method of preventing or treating Giardia infection in dogs and cats by adminstering Giardia which has been cultured in media containing bile so as to make it protectively immunogenic.
Type:
Grant
Filed:
November 23, 1993
Date of Patent:
April 30, 1996
Assignee:
University Technologies International, Inc.
Inventors:
Merle E. Olson, Howard Ceri, Douglas W. Morck
Abstract: A method for treating a papilloma virus infection comprising topically administering hypericin which is effective to inhibit the replication, growth and/or the infectivity of the virus. The papilloma viruses include those capable of causing benign warts or a malignancy such as human papilloma virus-1 (HPV-1), HPV-2, HPV-6, HPV-11, HPV-16 and HPV-18.
Abstract: Novel attenuated strains of Aeromonas salmonicida are disclosed that are effective as live effective vaccines against furunculosis in fish. These vaccines may be administered by the immersion of fish in a solution of the vaccine. Methods of producing these strains and other strains having the identifying characteristics of these strains are also disclosed.
Abstract: Method for the production of a subunit vaccine against porcine parvovirus (PPV). The method is comprised of a first step wherein a recombinant protein VP2 of PPV is obtained by using the replication of a recombinant baculovirus wherein the gene corresponding to VP2 has been previously inserted in cells of a permissive host. The protein VP2 obtained in this invention has the capacity of forming empty chimeric capsids with high immunogenicity and can be provided as a vaccine formulation for protecting pigs against PPV infection. The recombinant baculovirus AcMNPV.pPPVEx8 expresses the VP2 of PPV in conditions making possible the formation of pseudo-viral capsids.
Type:
Grant
Filed:
January 27, 1993
Date of Patent:
March 12, 1996
Assignee:
Inmunologia Y Genetica, S.A.
Inventors:
Jose I. Casal Alvarez, Elena Cortes Valdes, Ana I. Ranz Casares, Carmen Vela Olmo, Kristian Dalsgaard
Abstract: There is described a positive calibrator/control composition for use in assays for the detection of antibodies to infectious disease agents. The composition includes a composite antibody of a nonspecific IgM immunoglobulin moiety covalently linked to a specific, non-IgM antibody moiety. Also described is an assay method which utilizes the positive calibrator or control composition.
Abstract: A breast cancer vaccine which comprises a mixture of tumor associated antigens (TAA) with low doses of recombinant interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF).
Abstract: The present invention concerns a method for the stabilization of proteins in an aqueous solution which is characterized in that one or several members of the heat shock protein (Hsp90) family are added to the aqueous solution containing protein.
Type:
Grant
Filed:
January 19, 1993
Date of Patent:
December 12, 1995
Inventors:
Ursula Jakob, Johannes Buchner, Hans Wiech, Richard Zimmermann, Rainer Rudolph
Abstract: An antigenic composition includes antigens obtainable from Campylobacter jejuni and may be used as a vaccine to induce protective antibodies against both Campylobacter coli and Campylobacter jejuni. The antigenic composition, and antisera specific to the antigens can be used to detect Campylobacter coli or Campylobacter jejuni infection. Diagnostic detection kits include the novel antigenic composition or antisera thereto.
Type:
Grant
Filed:
September 16, 1994
Date of Patent:
November 28, 1995
Assignee:
Enteric Research Laboratories Inc.
Inventors:
Martin J. Blaser, Richard T. Ellison, III, Zhi H. Pei
Abstract: An improved immunogenic composition against human gastrin 17 comprising the peptide pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Ser-Ser-Pro-Pro-Pro-Pro-Cys (SEQ ID NO.: 1) coupled to an immunogenic carrier and pharmaceutical compositions containing the same.
Type:
Grant
Filed:
November 12, 1993
Date of Patent:
November 21, 1995
Assignee:
Aphton Corp.
Inventors:
Philip C. Gevas, Stephen Grimes, Stephen L. Karr, Dov Michaeli, Robert Scibienski
Abstract: The invention relates to a latex agglutination method for the detection or determination of one partner of an antigen-antibody reaction, wherein, in order to suppress non-specific reactions, to, for example, Clq and rheumatoid factors the immunochemical reaction takes place in the presence of an immune complex which does not contain any antibody or antigen that is specific for one of the partners.
Abstract: A live or inactivated canine corona virus vaccine is provided which is derived from a virus of the novel antigenic type of the canine corona virus strain I-743 (CNCM, Institut Pasteur, Paris). A method for the preparation of this vaccine and the use of said vaccine in protecting susceptible animals against canine corona virus injection are also disclosed.
Type:
Grant
Filed:
August 3, 1994
Date of Patent:
November 7, 1995
Assignee:
Akzo N.V.
Inventors:
William Baxendale, William S. K. Chalmers
Abstract: A vaccination kit and protocol for using it are disclosed which results in immunity from infection by herpesvirus. A first formulation of an isolated viral glycoprotein is injected intramuscularly to result in systemic immunity. Later a second formulation including the isolated viral glycoprotein with an adjuvant is administered intranasally, or otherwise administered to the mucosal membranes. A level of both systemic and mucosal immunity is achieved such that viral infection, as well as symptomatic disease, is avoided. The method and the vaccine are exemplified by a vaccine for Bovine Herpesvirus 1.
Type:
Grant
Filed:
March 22, 1993
Date of Patent:
October 31, 1995
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Geoffrey J. Letchworth, III, Barbara A. Israel
Abstract: The invention is directed to a lectin derived carbohydrate binding-peptide which inhibits cell-mediated immune responses and has the amino acid sequence SPYGRC. The peptide binds terminally linked .alpha.-sialic acid (2.fwdarw.3).beta.Gal- and .alpha.-sialic (2.fwdarw.6).beta.Gal-structures and is a acid fragment of the S2 subunit of pertussis toxin produced by Bordetella pertussis.
Type:
Grant
Filed:
December 21, 1992
Date of Patent:
September 26, 1995
Assignee:
Alberta Research Council
Inventors:
Louis D. Heerze, Glen D. Armstrong, Richard Smith
Abstract: A medically important and useful conjugate comprising pertussis toxin (PT), or another antigen having similar physico-chemical properties, as the carrier protein component, coupled to a neutral or non-charged saccharide, particularly, the capsular polysaccharide of Streptococcus pneumoniae type 14 (Pn14), for use as an effective, non-toxic, and highly immunogenic vaccine is described. The invention is directed to a novel synthetic scheme wherein PT and like proteins, and a derivative of Pn14, and the like, were coupled at acidic pH via carbodiimide-mediated condensation to produce an immunogenic conjugate. The coupling procedure yielded a Pn14-PT conjugate in which the PT component was rendered non-toxic and both the PT and Pn14 components were immunogenic, as determined by the production of protective levels of both type-specific and neutralizing antibodies in mammals.
Type:
Grant
Filed:
August 21, 1992
Date of Patent:
August 29, 1995
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Rachel Schneerson, Lily Levi, John B. Robbins
Abstract: Pertactin (formerly 69 kDa protein) is recovered in stable biologically pure form having no detectable adenylate cyclase activity from fermentation broth from the fermentation of Bordetella pertussis as well as from the cells. The broth is processed to selectively remove pertussis toxin (PT) and filamentous haemagglutinin (FHA), the pertactin is precipitated by ammonium sulphate and the precipitate is dissolved in buffer at pH 6.0 to 8.5, the solution then is passed through hydroxyapatite and ion-exchange chromatograph columns before final ultrafiltration. Cells are extracted with urea and the extract ultrafiltered and diafiltered. The pertactin is precipitated from the extract and the precipitate processed as above. In a variation, the broth is contacted with ammonium sulphate to precipitate pertactin, PT and FHA, the precipitate is dissolved and the PT and FHA selectively removed, before the solution is passed to the chromatograph columns.
Type:
Grant
Filed:
November 6, 1992
Date of Patent:
August 22, 1995
Assignee:
Connaught Laboratories Limited
Inventors:
Gail Jackson, Raafat Fahim, Larry Tan, Pele Chong, John Vose, Michel Klein
Abstract: An isolated nucleic acid molecule encoding the gB glycoprotein of Infectious Laryngotracheitis Virus is disclosed. Also disclosed is incorporation of the gB gene into recombinant avipox virus for a vaccine used to immunize fowl.
Abstract: This invention involves a chemically transformed chicken hepatocyte derived cell line which is capable of efficiently supporting replication of infectious laryngotracheitis virus (ILTV) and methods for cultivating ILTV using this hepatocellular carcinoma cell line. The virus harvested from these continuous cell culture methods can be used as a vaccine against ILTV infection.
Abstract: An attenuated infectious laryngotracheitis virus (ILT) that has the antigenic and virulence characteristics of ECACC at Accession No. V89042602, produces an average pock diameter on chorio-allantoic membrane of commercial eggs between 1.0 and 3. mm, exhibits substantially reduced virulence in comparison to ILT SA2 strain, and results in substantially less weight loss in poultry as compared to poultry infected with SA2. A method of producing this ILT virus by serially passaging ILT viral strain SA2 in primary cell cultures followed by serial passaging in embryonated eggs. A method for preventing infection by ILT virus in birds by administering a vaccine with an effective amount sufficient to elicit an immune response.
Abstract: A peptide having an amino acid sequence represented by the following formula: Ser-Thr-Lys-Glu-Gly-Asp-Ser-Ser-Asn-Thr-Gly-Ala-Gly-Lys-Ala-Leu-Thr-Gly-Le u-Ser-Thr-Gly specifically reacts with antibodies against human parvovirus B19. Therefore, this peptide can be used in agents for detecting antibodies against human parvovirus B19 and in methods for detecting antibodies against human parvovirus B19.
Type:
Grant
Filed:
October 21, 1993
Date of Patent:
July 25, 1995
Assignee:
Shin-Etsu Chemical Co., Ltd.
Inventors:
Ken Yahata, Yasuyoshi Koumoto, Tohru Chiba, Tadasu Nunoue
Abstract: A kit for use in determining the dosages and administering testosterone for the treatment of hair loss and disorders involving the lubricating function of the skin.